Jump to content

Gregory Winter: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Line 15: Line 15:
In 2000 Winter founded a company called [http://www.domantis.com Domantis] to pioneer the use of domain antibodies, which use only the active portion of a full-sized antibody. Domantis was acquired by the pharmaceutical giant [[GlaxoSmithKline]] in December 2006.<ref>http://www.gsk.com/media/pressreleases/2006/2006_12_08_GSK939.htm</ref> Recently he founded another company, Bicycle Therapeutics which is trying to develop very small protein mimics based on a covalently bonded hydrophobic core.
In 2000 Winter founded a company called [http://www.domantis.com Domantis] to pioneer the use of domain antibodies, which use only the active portion of a full-sized antibody. Domantis was acquired by the pharmaceutical giant [[GlaxoSmithKline]] in December 2006.<ref>http://www.gsk.com/media/pressreleases/2006/2006_12_08_GSK939.htm</ref> Recently he founded another company, Bicycle Therapeutics which is trying to develop very small protein mimics based on a covalently bonded hydrophobic core.


In 1995, Winter won several international awards including the [[King Faisal International Prize]] for Medicine (Molecular Immunology) and in 1999 the Cancer Research Institute [[William B. Coley Award]]. Winter was formerly the Joint Head of the Division of Protein and [[Nucleic acid|Nucleic Acid]] Chemistry-Biotechnology, and is Deputy Director,<ref>[http://www2.mrc-lmb.cam.ac.uk/admin.html LMB Structure]</ref> at the [[Laboratory of Molecular Biology]], Cambridge, an institution funded by the UK [[Medical research|Medical Research]] Council. He was also Deputy Director of the MRC’s Centre for [[Protein engineering|Protein Engineering]] until its absorption into the [[Laboratory of Molecular Biology]]. Winter was knighted in 2004. He is a Fellow of [[Trinity College, Cambridge|Trinity College]], University of Cambridge. He is a member of the Advisory Council for the [[Campaign for Science and Engineering]].<ref name="CaSE Advisory Council">{{cite web|url=http://www.sciencecampaign.org.uk/about/who/advisory.htm|title=Advisory Council of the Campaign for Science and Engineering|accessdate=2011-02-11}}</ref>
He was elected a [[Fellow of the Royal Society]] in 1990 and awarded the [[Royal Medal]] by the society in 2011 "''for his pioneering work in protein engineering and therapeutic monoclonal antibodies, and his contributions as an inventor and entrepreneur''" <ref> {{cite web|url = http://royalsociety.org/news/RS-announces-2011-Copley/| title = Royal Society announces 2011 Copley Medal recipient| publisher = Royal Society|accessdate = 2012-02-23}} </ref>. In 1995, Winter won several international awards including the [[King Faisal International Prize]] for Medicine (Molecular Immunology) and in 1999 the Cancer Research Institute [[William B. Coley Award]]. Winter was formerly the Joint Head of the Division of Protein and [[Nucleic acid|Nucleic Acid]] Chemistry-Biotechnology, and is Deputy Director,<ref>[http://www2.mrc-lmb.cam.ac.uk/admin.html LMB Structure]</ref> at the [[Laboratory of Molecular Biology]], Cambridge, an institution funded by the UK [[Medical research|Medical Research]] Council. He was also Deputy Director of the MRC’s Centre for [[Protein engineering|Protein Engineering]] until its absorption into the [[Laboratory of Molecular Biology]]. Winter was knighted in 2004. He is a Fellow of [[Trinity College, Cambridge|Trinity College]], University of Cambridge. He is a member of the Advisory Council for the [[Campaign for Science and Engineering]].<ref name="CaSE Advisory Council">{{cite web|url=http://www.sciencecampaign.org.uk/about/who/advisory.htm|title=Advisory Council of the Campaign for Science and Engineering|accessdate=2011-02-11}}</ref>


From July 2012, Winter will take over from [[Martin Rees, Baron Rees of Ludlow|Martin Rees]], as Master of [[Trinity College, Cambridge]].<ref>http://www.number10.gov.uk/news/master-of-trinity/</ref><ref>http://news.admin.cam.ac.uk/news/2011/12/16/master-of-trinity-college-cambridge/</ref>
From July 2012, Winter will take over from [[Martin Rees, Baron Rees of Ludlow|Martin Rees]], as Master of [[Trinity College, Cambridge]].<ref>http://www.number10.gov.uk/news/master-of-trinity/</ref><ref>http://news.admin.cam.ac.uk/news/2011/12/16/master-of-trinity-college-cambridge/</ref>

Revision as of 17:12, 23 February 2012

For the American journalist, see Greg Winter (journalist).

Sir Gregory Paul Winter, CBE, FRS (born April 1951) is a British biochemist, a pioneer of therapeutic monoclonal antibodies. He invented techniques to both humanise (1986) and, later, to fully humanise using phage display, antibodies for therapeutic uses.[1] Before this groundbreaking work antibodies had failed to live up to their potential because they had been derived from mice. He is a Fellow of Trinity College, Cambridge and has been named as the next Master.[2] He is Deputy Director of the Laboratory of Molecular Biology, Medical Research Council, and Head of the Division of Protein and Nucleic Acids Chemistry.[3]

Life

He graduated from Trinity College, Cambridge in 1973, and did PhD and postdoctoral work at LMB.[4]

He founded Cambridge Antibody Technology, in 1989, and Bicycle Therapeutics.[5] He is on the Scientific Advisory Board of Covagen.[6] [7]

In 1989 Winter was a founder of Cambridge Antibody Technology, which was one of the early commercial biotech companies involved in antibody engineering. One of the most successful antibody drugs developed was HUMIRA (adalimumab), which was discovered by Cambridge Antibody Technology as D2E7 and developed and marketed by Abbott Laboratories. HUMIRA, an antibody to TNF alpha, was the world's first fully human antibody,[8] which achieved annual sales exceeding $1bn [9] therefore achieving blockbuster status.[10] Cambridge Antibody Technology was acquired by Astrazeneca in 2006 for £702m.[11]

In 2000 Winter founded a company called Domantis to pioneer the use of domain antibodies, which use only the active portion of a full-sized antibody. Domantis was acquired by the pharmaceutical giant GlaxoSmithKline in December 2006.[12] Recently he founded another company, Bicycle Therapeutics which is trying to develop very small protein mimics based on a covalently bonded hydrophobic core.

He was elected a Fellow of the Royal Society in 1990 and awarded the Royal Medal by the society in 2011 "for his pioneering work in protein engineering and therapeutic monoclonal antibodies, and his contributions as an inventor and entrepreneur" [13]. In 1995, Winter won several international awards including the King Faisal International Prize for Medicine (Molecular Immunology) and in 1999 the Cancer Research Institute William B. Coley Award. Winter was formerly the Joint Head of the Division of Protein and Nucleic Acid Chemistry-Biotechnology, and is Deputy Director,[14] at the Laboratory of Molecular Biology, Cambridge, an institution funded by the UK Medical Research Council. He was also Deputy Director of the MRC’s Centre for Protein Engineering until its absorption into the Laboratory of Molecular Biology. Winter was knighted in 2004. He is a Fellow of Trinity College, University of Cambridge. He is a member of the Advisory Council for the Campaign for Science and Engineering.[15]

From July 2012, Winter will take over from Martin Rees, as Master of Trinity College, Cambridge.[16][17]

Works

See also

Notes & References

  1. ^ http://www.nature.com/nature/journal/v348/n6301/abs/348552a0.html
  2. ^ http://www.takedasf.com/corporate/winter.htm
  3. ^ http://www.f-star.com/scientific_advisors/3/sir-gregory-winter-chairman
  4. ^ http://www.heptares.com/sab/
  5. ^ http://investing.businessweek.com/businessweek/research/stocks/private/person.asp?personId=23316112&privcapId=72510621&previousCapId=26322&previousTitle=CEPHALON%20INC
  6. ^ http://www.covagen.com/index.php?id=113
  7. ^ http://www.covagen.com/index.php?id=114
  8. ^ http://www.nature.com/nbt/journal/v25/n4/full/nbt0407-380.html
  9. ^ http://telegraph.uk-wire.com/cgi-bin/articles/200601251501444434X.html
  10. ^ http://en.wikipedia.org/wiki/Pharmaceutical_drug#Other.2Frelated_topics
  11. ^ http://www.astrazeneca.com/media/latest-press-releases/2006/5266?itemId=3891617
  12. ^ http://www.gsk.com/media/pressreleases/2006/2006_12_08_GSK939.htm
  13. ^ "Royal Society announces 2011 Copley Medal recipient". Royal Society. Retrieved 2012-02-23.
  14. ^ LMB Structure
  15. ^ "Advisory Council of the Campaign for Science and Engineering". Retrieved 2011-02-11.
  16. ^ http://www.number10.gov.uk/news/master-of-trinity/
  17. ^ http://news.admin.cam.ac.uk/news/2011/12/16/master-of-trinity-college-cambridge/

External links

  • The Scientific Founders of Bicycle Therapeutics Ltd. – Christian Heinis and Sir Greg Winter, FRS.

Template:Persondata


Stub icon

This United Kingdom biographical article related to medicine is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about a British scientist is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Gregory_Winter&oldid=478453128"